Search clinical trials for: Denosumab (Prolia)

Total 675 results

Luye Pharma Group Ltd.
Parexel

Completed

A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

Healthy

Germany
Rudolf Wuethrich

Completed

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients (POSTOP)

Chronic Kidney Disease | Osteoporosis

Switzerland
Turku University Hospital
Amgen

Completed

Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (ProliaHip)

Hip Osteoarthritis

Finland
Mishaela Rubin

Terminated

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

Diabetes Mellitus, Type 2 | Osteoporosis

United States
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

Poland
Indiana University

Withdrawn

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Vasculitis | Osteoporosis | Dermatomyositis | Juvenile Rheumatoid Arthritis | Glucocorticoid-induced Osteoporosis | Polyarthritis | Systemic Lupus Erythematosis

United States
HealthEast Care System
Amgen

Completed

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Osteoporosis | Bone Fracture

United States
Borstkanker Onderzoek Groep
Amgen

Withdrawn

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO)

Breast Neoplasms

Netherlands
Alvotech Swiss AG

Completed

AVT03 With Prolia in Healthy Male Subjects

Healthy Male Subjects

New Zealand
Shanghai Henlius Biotech

Completed

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Healthy Male Volunteers

China
Mayo Clinic

Completed

Osteoclast Inhibition and Bone Formation

Aging | Bone Loss

United States
Columbia University
Amgen

Recruiting

Romosozumab/Denosumab Study for Premenopausal IOP

Premenopausal Idiopathic Osteoporosis

United States
Massachusetts General Hospital
Emory University; University of Rochester; Amgen; University Hospitals Cleveland...

Unknown

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Multiple Myeloma

United States
Amgen

Completed

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France (PILOTE)

Post Menopausal Osteoporosis

France
Seoul National University Bundang Hospital

Unknown

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Spine Deformity

Korea, Republic of
Qilu Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Healthy People

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Hans Mallmin

Completed

Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Osteoarthritis, Hip | Ambulation Difficulty

Sweden
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Terminated

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Spinal Cord Injury | Secondary Osteoporosis

United States
Enzene Biosciences Ltd.
Alkem Laboratories Ltd

Recruiting

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Healthy Male Subjects

Bulgaria, Poland
Lambda Therapeutic Research Ltd.
Intas Pharmaceutical Limited (Biopharma Division)

Recruiting

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

India
Xentria, Inc.

Not yet recruiting

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

Healthy Participants
Thomas Nickolas, MD MS

Terminated

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients (ProliaKTx)

Osteoporosis | Kidney Transplant; Complications | Renal Osteodystrophy

United States
Shanghai Biomabs Pharmaceutical Co., Ltd.

Recruiting

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Postmenopausal Osteoporosis

China
Felicia Cosman, MD
Crozer-Keystone Health System; Radius Health, Inc.

Recruiting

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Osteoporosis, Postmenopausal

United States
University of Southern California
Orthopaedic Institute for Children

Withdrawn

Longjohn Amgen Study - Effect of Denosumab... (EDRPBLFHR)

Arthroplasty, Replacement, Hip

United States
Tomidahama Hospital

Unknown

Effects of Denosumab Therapy for Japanese

Osteoporosis

Japan
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Amgen

Not yet recruiting

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

Osteoporosis
Stanley Dudrick's Memorial Hospital

Completed

Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients (Denoz)

Metabolic Bone Disease

Poland
Shenzhen People's Hospital

Recruiting

Denosumab vs Zoledronate After Lumbar Fusion

Osteopenia | Lumbar Spondylolisthesis

China
Kyoto Prefectural University of Medicine

Active, not recruiting

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Breast Cancer

Japan
The Affiliated Hospital of Qingdao University

Not yet recruiting

Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty

Osteoarthritis, Knee
University of Manitoba
McMaster University; University of Toronto

Completed

The Efficacy of Denosumab in Active Crohn's Disease

Crohn Disease

Canada
Amgen

Completed

Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose

Healthy Volunteer

United States
Alvotech Swiss AG

Active, not recruiting

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND (ALVOBOND)

Osteoporosis, Postmenopausal

South Africa
Elizabeth Shane
Creighton University

Completed

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Adult Idiopathic Generalized Osteoporosis

United States
University of Alabama at Birmingham
University of Auckland, New Zealand

Completed

Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions

Gout

United States
Ersi Voskaridou

Completed

Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis

Osteoporosis | Thalassemia Major

Greece
Martin Blomberg Jensen

Completed

TNFSF11 Inhibition and Fertility: a Prospective Study

Infertility | Testis | Sperm

Denmark
Amgen
One Amgen Center Drive; THOUSAND OAKS; CA; 91320-1799; USA

Completed

Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

Osteoporosis, Postmenopausal

Czechia, Slovakia
Massachusetts General Hospital
Amgen

Completed

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Anorexia Nervosa | Bone Loss | Eating Disorder | Bone Density | Atypical Anorexia Nervosa

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Amgen

Completed

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Osteoporosis | Osteopenia
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Amgen

Completed

Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty

Revision Surgery of Total Hip Arthroplasty

United Kingdom
Hebei Medical University Third Hospital

Unknown

Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone (D-Gct)

Giant Cell Tumor of Bone

China
Amgen

Completed

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Cancer | Cataract | Prostate Cancer | Osteoporosis | Osteopenia | Low Bone Mineral Density

United States, Canada, Czechia, Poland, Russian Federation, Slovakia, Hungary, South Africa, Greece, Bulgaria, France, Ukraine, Australia, Latvia, India, Slovenia, New Zealand, Mexico
Shenzhen People's Hospital

Completed

Denosumab and Osteoporotic Vertebral Compression Fracture

Osteoporotic Vertebral Compression Fracture

China
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Postmenopausal

China
Martin Blomberg Jensen

Completed

Denosumab and Male Infertility: a RCT

Infertility, Male

Denmark

Search clinical trials for: Denosumab (Prolia)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations